In the first nine months of this year, Pfizer’s (PFE) vaccines sales grew ~7% YoY (year-over-year) to $4.7 billion from $4.4 billion. US vaccine sales grew ~2% to $2.7 billion, while international vaccine sales grew ~15% YoY to $2.0 billion. Internationally, Pfizer’s vaccine operations grew ~13% YoY.
In the third quarter, Pfizer’s vaccine revenue grew ~12% YoY to $1.8 billion. US and international vaccines sales grew ~14% and 9% YoY, respectively, to $1.1 billion and $695.0 million.
Trumenba and TicoVac revenue
Revenue from Trumenba, a meningococcal group B vaccine, grew ~20% YoY to $95.0 million in the first nine months of this year, and ~46% YoY to $61.0 million in the third quarter. Revenue from Pfizer’s TicoVac, a tick-borne encephalitis vaccine, grew ~36% YoY to $162.0 million in the first nine months of this year, and 31% YoY to $57.0 million from $43.0 million in the third quarter.
In the third quarter, revenue for vaccine peers GlaxoSmithKline (GSK), Merck (MRK), and Sanofi (SNY) grew ~2.78%, ~4.54%, and 2.66% YoY, respectively, to $10.5 billion, $10.8 billion, and $10.9 billion. Pfizer’s and Merck’s revenue growth could boost the First Trust NASDAQ Pharmaceutical ETF (FTXH), of which PFE and MRK comprise ~9.56% and ~5.10%, respectively.